Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/17512433.2021.1964359 http://scihub22266oqcxt.onion/10.1080/17512433.2021.1964359 34402362!8425471!34402362     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34402362&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Expert+Rev+Clin+Pharmacol 2021 ; 14 (10): 1289-1294 Nephropedia Template TP {{tp|p=34402362|t=2021. Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients |pdf=|usr=}}{{34402362}} gab.com Text Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients JO: Expert Rev Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=34402362 #FOAvip PURPOSE: We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients. METHODS: We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution. RESULTS: 50 patients were included. Mean follow-up was 42.5 +/- 10 days. No baseline differences were found between patients with ARDS (30%) and those without ARDS at admission. Patients with PE resolution (84%) were younger (P = 0.03), had a shorter duration of fondaparinux therapy (9.9 +/- 3.8 vs 15.8 +/- 7.5 days; P = 0.0015) and length of hospitalization (36 +/- 8 vs 46 +/- 9 days: P = 0.0023) compared with those without PE resolution. 2 patients experienced major bleedings. At multivariate analysis the time to edoxaban switch was the only predictor of the PE resolution (HR: 0.92; 95% C.I. 0.86 to 0.99). CONCLUSION: Edoxaban was an effective and safe treatment for acute PE in COVID-19 setting. Twit Text FOAVip Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients ????Expert Rev Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=34402362 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34402362 #FOAvip English Wikipedia <ref>{{Cite pmid|34402362}}</ref> Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients #MMPMID34402362 Langella V; Bottino R; Asti A; Maresca G; Di Palma G; Pomponi D; Sassone C; Imbalzano E; Russo V Expert Rev Clin Pharmacol 2021[Oct]; 14 (10): 1289-1294 PMID34402362show ga PURPOSE: We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients. METHODS: We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution. RESULTS: 50 patients were included. Mean follow-up was 42.5 +/- 10 days. No baseline differences were found between patients with ARDS (30%) and those without ARDS at admission. Patients with PE resolution (84%) were younger (P = 0.03), had a shorter duration of fondaparinux therapy (9.9 +/- 3.8 vs 15.8 +/- 7.5 days; P = 0.0015) and length of hospitalization (36 +/- 8 vs 46 +/- 9 days: P = 0.0023) compared with those without PE resolution. 2 patients experienced major bleedings. At multivariate analysis the time to edoxaban switch was the only predictor of the PE resolution (HR: 0.92; 95% C.I. 0.86 to 0.99). CONCLUSION: Edoxaban was an effective and safe treatment for acute PE in COVID-19 setting. |*SARS-CoV-2[MESH] |Adult[MESH] |Aged[MESH] |COVID-19/*complications[MESH] |Factor Xa Inhibitors/*therapeutic use[MESH] |Female[MESH] |Fondaparinux/therapeutic use[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Multivariate Analysis[MESH] |Proportional Hazards Models[MESH] |Pulmonary Embolism/*drug therapy/etiology[MESH] |Pyridines/*therapeutic use[MESH] |Respiratory Distress Syndrome[MESH] |Retrospective Studies[MESH]Edoxaban for the treatment of pulmonary embolism in hospitalized COVID(epmc).pdf DeepDyve Pubget Overpricing